

Emanuele Angelucci

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5512291/emanuele-angelucci-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

239
papers

10,261
citations

55
h-index

94
g-index

256
ext. papers

11,805
ext. citations

6.6
avg, IF

5.42
L-index

| # | Paper | IF | Citations |
|-----|---|------|-----------|
| 239 | Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major.. <i>Annals of Hematology</i> , 2022 , 101, 655 | 3 | 0 |
| 238 | Iron-mediated tissue damage in acquired ineffective erythropoiesis disease: It's more a matter of burden or more of exposure to toxic iron form?. <i>Leukemia Research</i> , 2022 , 114, 106792 | 2.7 | 1 |
| 237 | Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice. <i>Cancer</i> , 2021 , 127, 2015-2024 | 6.4 | 0 |
| 236 | Outcome of T-cell-replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2021 , 127, 2507-2514 | 6.4 | 2 |
| 235 | Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1944-1952 | 4.4 | 1 |
| 234 | Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1223-1233 | 2.2 | 25 |
| 233 | Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2194-2202 | 4.4 | 1 |
| 232 | Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 53 | 22.4 | 9 |
| 231 | Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 81 | 22.4 | 4 |
| 230 | Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , 2021 , 35, 215-224 | 10.7 | 15 |
| 229 | Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia. <i>Clinical Cancer Research</i> , 2021 , 27, 843-851 | 12.9 | 11 |
| 228 | Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2021 , 56, 622-634 | 4.4 | 2 |
| 227 | Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). <i>American Journal of Hematology</i> , 2021 , 96, 69-79 | 7.1 | 11 |
| 226 | A large co-operative biological and clinical study to better understand and improve treatment of the rare t(8;16)(p11;p13) acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021 , 192, 800-802 | 4.5 | |
| 225 | Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1593-1602 | 4.4 | 1 |
| 224 | Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 46 | 22.4 | 24 |
| 223 | Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. <i>Blood Advances</i> , 2020 , 4, 2073-2083 | 7.8 | 21 |

| | | | |
|-----|---|------|----|
| 222 | Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 296-304 | 2 | 3 |
| 221 | Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia. <i>Leukemia</i> , 2020 , 34, 2766-2775 | 10.7 | 10 |
| 220 | Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 698-703 | 4.7 | 7 |
| 219 | Consistency matters: measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignancies. <i>Quality of Life Research</i> , 2020 , 29, 815-823 | 3.7 | 11 |
| 218 | Impact of total body irradiation- vs chemotherapy-based myeloablative conditioning on outcomes of haploidentical hematopoietic cell transplantation for acute myelogenous leukemia. <i>American Journal of Hematology</i> , 2020 , 95, 1200 | 7.1 | 6 |
| 217 | Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes. <i>Annals of Internal Medicine</i> , 2020 , 173, 595-596 | 8 | 1 |
| 216 | Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial. <i>Annals of Internal Medicine</i> , 2020 , 172, 513-522 | 8 | 37 |
| 215 | Can any new thalassemia therapy achieve a better than 97.4% cure rate?. <i>American Journal of Hematology</i> , 2020 , 95, 1233-1234 | 7.1 | 0 |
| 214 | Unintentional human leukocyte antigen-mismatched haematopoietic cell transplant: clinical course and root cause analysis. <i>British Journal of Haematology</i> , 2020 , 191, e35-e37 | 4.5 | |
| 213 | Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. <i>Blood Advances</i> , 2020 , 4, 3900-3912 | 7.8 | 12 |
| 212 | Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis. <i>Cancer Medicine</i> , 2019 , 8, 7567-7576 | 4.8 | 3 |
| 211 | Iron Chelation Therapy in MDS ¶The Final Answer. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, S75-S76 | 2 | 2 |
| 210 | Iron Toxicity and Hemopoietic Cell Transplantation: Time to Change the Paradigm. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019 , 11, e2019030 | 3.2 | 7 |
| 209 | Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 2341-2346 | 5.1 | 28 |
| 208 | A new medical therapy for anemia in thalassemia. <i>Blood</i> , 2019 , 133, 1267-1268 | 2.2 | 0 |
| 207 | Myeloablative Unrelated Cord Blood Transplantation in Adolescents and Young Adults with Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2438-2446 | 4.7 | 4 |
| 206 | Graft versus host disease in unmanipulated haploidentical marrow transplantation with a modified post-transplant cyclophosphamide (PT-CY) regimen: an update on 425 patients. <i>Bone Marrow Transplantation</i> , 2019 , 54, 708-712 | 4.4 | 10 |
| 205 | Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2167-2171 | 4.7 | 35 |

| | | | |
|-----|--|------|----|
| 204 | Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies. <i>Value in Health</i> , 2019 , 22, 1303-1310 | 3.3 | 8 |
| 203 | Selecting β -Thalassemia Patients for Gene Therapy: A Decision-Making Algorithm. <i>Blood</i> , 2019 , 134, 972-972 | | 2 |
| 202 | Iron Overload 2019 , 353-356 | | |
| 201 | Update of the GIMEMA MDS0306 study: Deferasirox for lower risk transfusion-dependent patients with myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2019 , 102, 442-443 | 3.8 | 1 |
| 200 | Use of <i>Aspergillus fumigatus</i> real-time PCR in bronchoalveolar lavage samples (BAL) for diagnosis of invasive aspergillosis, including azole-resistant cases, in high risk haematology patients: the need for a combined use with galactomannan. <i>Medical Mycology</i> , 2019 , 57, 987-996 | 3.9 | 12 |
| 199 | Long-term response in refractory AML following azacitidine-failed MDS by salvage decitabine-bridged allogeneic transplantation. <i>Blood Research</i> , 2019 , 54, 288-290 | 1.4 | |
| 198 | Efficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximab. <i>Infection</i> , 2019 , 47, 59-65 | 5.8 | 6 |
| 197 | HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 114-120 | 4.7 | 14 |
| 196 | Advances in transplantation and gene therapy in transfusion-dependent β -thalassemia. <i>Advances in Cell and Gene Therapy</i> , 2019 , 2, e25 | 1.2 | 1 |
| 195 | AISF position paper on HCV in immunocompromised patients. <i>Digestive and Liver Disease</i> , 2019 , 51, 10-23 | 3.3 | 4 |
| 194 | Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib. <i>Cancer</i> , 2018 , 124, 2228-2237 | 6.4 | 20 |
| 193 | Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 1357-1366 | 4.9 | 6 |
| 192 | Estimates of Environmental Exposure to Radiofrequency Electromagnetic Fields and Risk of Lymphoma Subtypes. <i>Radiation Research</i> , 2018 , 189, 541-547 | 3.1 | 2 |
| 191 | Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2904-2910 | 1.9 | 5 |
| 190 | Late Effects Screening Guidelines after Hematopoietic Cell Transplantation (HCT) for Hemoglobinopathy: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1313-1321 | 4.7 | 24 |
| 189 | A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1243-1249 | 4.7 | 36 |
| 188 | De-Escalation and Discontinuation of Empirical Antibiotic Treatment in a Cohort of Allogeneic Hematopoietic Stem Cell Transplantation Recipients during the Pre-Engraftment Period. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1721-1726 | 4.7 | 22 |
| 187 | A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. <i>Leukemia</i> , 2018 , 32, 413-418 | 10.7 | 42 |

| | | | |
|-----|---|------|----|
| 186 | Impact of HLA Disparity in Haploidentical Bone Marrow Transplantation Followed by High-Dose Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 119-126 | 4.7 | 25 |
| 185 | Cardiogenic Shock during First Infusion of Anthracycline Chemotherapy in a Patient with Hodgkin Lymphoma: An Unusual Event. <i>Cardiology</i> , 2018 , 139, 7-10 | 1.6 | 0 |
| 184 | A storm in the niche: Iron, oxidative stress and haemopoiesis. <i>Blood Reviews</i> , 2018 , 32, 29-35 | 11.1 | 41 |
| 183 | Pre-Engraftment Bloodstream Infections after Allogeneic Hematopoietic Cell Transplantation: Impact of T Cell-Replete Transplantation from a Haploidentical Donor. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 109-118 | 4.7 | 31 |
| 182 | Haploidentical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission Tomography. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2501-2508 | 4.7 | 15 |
| 181 | Non-transferrin-bound iron and oxidative stress during allogeneic hemopoietic stem cell transplantation in patients with or without iron overload. <i>American Journal of Hematology</i> , 2018 , 93, E250-E252 | 7.1 | 9 |
| 180 | Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the. <i>Haematologica</i> , 2018 , 103, 1345-1350 | 6.6 | 26 |
| 179 | High vs low dose cyclosporine-a, after allogeneic marrow transplantation in leukemia: Long term follow up of a randomized study. <i>American Journal of Hematology</i> , 2018 , 93, E185 | 7.1 | |
| 178 | Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 130, 27-35 | 7 | 17 |
| 177 | Visceral leishmaniasis in hematopoietic cell transplantation: Case report and review of the literature. <i>Journal of Infection and Chemotherapy</i> , 2018 , 24, 990-994 | 2.2 | 9 |
| 176 | Hematopoietic Cell Transplantation in Thalassemia and Sickle Cell Disease: Report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry: 2000-2017. <i>Blood</i> , 2018 , 132, 168-168 | 2.2 | 3 |
| 175 | Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 689-696 | 2.2 | 81 |
| 174 | Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 110 | 22.4 | 29 |
| 173 | Foscarnet treatment of cytomegalovirus infection in haploidentical or unrelated donor transplants. <i>Bone Marrow Transplantation</i> , 2018 , 53, 1560-1567 | 4.4 | 4 |
| 172 | Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, e401-e419 | 2 | 37 |
| 171 | Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 109-118 | 4.7 | 43 |
| 170 | Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. <i>British Journal of Haematology</i> , 2017 , 177, 741-750 | 4.5 | 16 |
| 169 | Hematopoietic cell transplant in thalassemia 2017 , 246-254 | | |

| | | | |
|-----|---|------|-----|
| 168 | Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. <i>Leukemia</i> , 2017 , 31, 2449-2457 | 10.7 | 26 |
| 167 | Haploidentical bone marrow transplantation in patients with advanced myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2017 , 92, E117-E119 | 7.1 | 3 |
| 166 | Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes. <i>Leukemia Research</i> , 2017 , 62, 108-115 | 2.7 | 16 |
| 165 | Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. <i>Lupus Science and Medicine</i> , 2017 , 4, e000187 | 4.6 | 10 |
| 164 | Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , 2017 , 18, 1076-1088 | 21.7 | 72 |
| 163 | Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. <i>Clinical Infectious Diseases</i> , 2017 , 65, 1884-1896 | 11.6 | 63 |
| 162 | Myelodysplastic Syndromes and Iron Chelation Therapy. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2017 , 9, e2017021 | 3.2 | 12 |
| 161 | Should every Patient with MDS get Iron Chelation - Probably Yes. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2017 , 9, e2017055 | 3.2 | 1 |
| 160 | Halting pro-survival autophagy by TGF β inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients. <i>Leukemia</i> , 2016 , 30, 640-8 | 10.7 | 46 |
| 159 | Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy. <i>BMJ Supportive and Palliative Care</i> , 2016 , 6, 80-8 | 2.2 | 13 |
| 158 | Treosulfan-fludarabine-thiotepa conditioning before allogeneic haemopoietic stem cell transplantation for patients with advanced lympho-proliferative disease. A single centre study. <i>Hematological Oncology</i> , 2016 , 34, 17-21 | 1.3 | 4 |
| 157 | Management of iron overload before, during, and after hematopoietic stem cell transplantation for thalassemia major. <i>Annals of the New York Academy of Sciences</i> , 2016 , 1368, 115-21 | 6.5 | 30 |
| 156 | Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL). <i>British Journal of Haematology</i> , 2016 , 172, 879-88 | 4.5 | 25 |
| 155 | Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-2010. <i>Bone Marrow Transplantation</i> , 2016 , 51, 536-41 | 4.4 | 101 |
| 154 | The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia. <i>Annals of Hematology</i> , 2016 , 95, 211-9 | 3 | 13 |
| 153 | Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. <i>Human Molecular Genetics</i> , 2016 , 25, 1663-76 | 5.6 | 39 |
| 152 | Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2370-4 | 1.9 | 4 |
| 151 | B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL). <i>Leukemia and Lymphoma</i> , 2016 , 57, 2375-81 | 1.9 | 5 |

| | | | |
|-----|---|------|-----|
| 150 | N-acetyltransferase polymorphisms are associated with risk of lymphoma subtypes. <i>Hematological Oncology</i> , 2016 , 34, 79-83 | 1.3 | 2 |
| 149 | Biosimilars G-CSF versus originator G-CSF in post allotransplant recovery. A case-control study. <i>American Journal of Hematology</i> , 2016 , 91, E7-8 | 7.1 | 1 |
| 148 | Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival. <i>Haematologica</i> , 2016 , 101, e245-8 | 6.6 | 18 |
| 147 | Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3627-3637 | 2.2 | 147 |
| 146 | Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1983-1987 | 4.7 | 58 |
| 145 | A genome-wide association study by ImmunoChip reveals potential modifiers in myelodysplastic syndromes. <i>Experimental Hematology</i> , 2016 , 44, 1034-1038 | 3.1 | 3 |
| 144 | Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome - Emphasis on optimized dosing schedules and new formulations. <i>Leukemia Research</i> , 2015 , 39, 1028-33 | 2.7 | 16 |
| 143 | Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia. <i>Leukemia Research</i> , 2015 , 39, 957-63 | 2.7 | 27 |
| 142 | Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. <i>Lancet Oncology</i> , 2015 , 16, 1506-1514 | 21.7 | 60 |
| 141 | Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2015 , 39, 859-65 | 2.7 | 12 |
| 140 | Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2015 , 168, 361-70 | 4.5 | 40 |
| 139 | Reproducibility of liver iron concentration measured on a biopsy sample: a validation study in vivo. <i>American Journal of Hematology</i> , 2015 , 90, 87-90 | 7.1 | 7 |
| 138 | Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. <i>Journal of the National Cancer Institute</i> , 2015 , 107, djv279 | 9.7 | 107 |
| 137 | Dramatic erythroid response to low-dose thalidomide in two patients with transfusion independent thalassemia and severe post-transfusional alloimmune hemolysis. <i>American Journal of Hematology</i> , 2015 , 90, E141 | 7.1 | 14 |
| 136 | Another Step Forward in Iron Chelation Therapy. <i>Acta Haematologica</i> , 2015 , 134, 231-2 | 2.7 | 3 |
| 135 | Risk of lymphoma subtypes and dietary habits in a Mediterranean area. <i>Cancer Epidemiology</i> , 2015 , 39, 1093-8 | 2.8 | 8 |
| 134 | Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015 , 26, 185-192 | 10.3 | 48 |
| 133 | Acute pancreatitis following brentuximab vedotin therapy for refractory Hodgkin lymphoma: a case report. <i>Drugs in R and D</i> , 2014 , 14, 9-11 | 3.4 | 17 |

| | | | |
|-----|--|------|-----|
| 132 | Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. <i>Leukemia</i> , 2014 , 28, 642-8 | 10.7 | 48 |
| 131 | Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. <i>Nature Genetics</i> , 2014 , 46, 1233-8 | 36.3 | 108 |
| 130 | Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. <i>Blood</i> , 2014 , 123, 2333-42 | 2.2 | 119 |
| 129 | Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia. <i>Haematologica</i> , 2014 , 99, 788-93 | 6.6 | 57 |
| 128 | Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. <i>Haematologica</i> , 2014 , 99, 811-20 | 6.6 | 241 |
| 127 | Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial). <i>European Journal of Haematology</i> , 2014 , 92, 527-36 | 3.8 | 76 |
| 126 | HIF-1 α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target. <i>Clinical Cancer Research</i> , 2014 , 20, 847-58 | 12.9 | 40 |
| 125 | Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes. <i>Annals of Oncology</i> , 2014 , 25, 447-54 | 10.3 | 31 |
| 124 | Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation. <i>Annals of Hematology</i> , 2013 , 92, 1271-80 | 3 | 3 |
| 123 | Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2013 , 88, 581-8 | 7.1 | 46 |
| 122 | Do matrix metalloproteinase-1 and glucose-6-phosphate dehydrogenase gene polymorphisms interact in promoting lymphoma development?. <i>Leukemia and Lymphoma</i> , 2013 , 54, 2734-5 | 1.9 | |
| 121 | Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients. <i>Journal of Pathology</i> , 2013 , 229, 87-98 | 9.4 | 23 |
| 120 | Safety of hematopoietic stem cell donation in glucose 6 phosphate dehydrogenase-deficient donors. <i>Bone Marrow Transplantation</i> , 2013 , 48, 36-9 | 4.4 | 3 |
| 119 | Cardiovascular events and intensity of treatment in polycythemia vera. <i>New England Journal of Medicine</i> , 2013 , 368, 22-33 | 59.2 | 506 |
| 118 | Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. <i>Blood</i> , 2013 , 122, 1072-8 | 2.2 | 176 |
| 117 | High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program. <i>Haematologica</i> , 2013 , 98, 1718-25 | 6.6 | 32 |
| 116 | Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre study. <i>Annals of Hematology</i> , 2012 , 91, 527-32 | 3 | 2 |
| 115 | Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients. <i>American Journal of Hematology</i> , 2012 , 87, 1047-51 | 7.1 | 21 |

| | | | |
|-----|---|------|-----|
| 114 | CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease. <i>Haematologica</i> , 2012 , 97, 568-71 | 6.6 | 21 |
| 113 | Household contact with pets and birds and risk of lymphoma. <i>Cancer Causes and Control</i> , 2011 , 22, 159-65.8 | | 3 |
| 112 | Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine. <i>Leukemia</i> , 2011 , 25, 1910-3 | 10.7 | 35 |
| 111 | Hematopoietic stem cell transplantation in thalassemia. <i>Hematology American Society of Hematology Education Program</i> , 2010 , 2010, 456-62 | 3.1 | 55 |
| 110 | Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3644-52 | 2.2 | 209 |
| 109 | Hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: long-term results of a retrospective study on behalf of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Haematologica</i> , 2010 , 95, 983-8 | 6.6 | 43 |
| 108 | The evolving clinical scenario of myelodysplastic syndrome: the need for a complete and up to date upfront diagnostic assessment. <i>European Journal of Internal Medicine</i> , 2010 , 21, 490-5 | 3.9 | 6 |
| 107 | Patient satisfaction with nursing staff in bone marrow transplantation and hematology units. <i>Transplantation Proceedings</i> , 2010 , 42, 2257-63 | 1.1 | 1 |
| 106 | Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. <i>Blood</i> , 2010 , 116, 2875-83 | 2.2 | 65 |
| 105 | Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. <i>Haematologica</i> , 2010 , 95, 476-84 | 6.6 | 116 |
| 104 | Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. <i>Blood</i> , 2010 , 115, 2755-62 | 2.2 | 199 |
| 103 | A case of fatal overwhelming microgranular variant (M3v) of acute promyelocytic leukemia with extensive extramedullary involvement. <i>International Journal of Hematology</i> , 2010 , 91, 551-2 | 2.3 | |
| 102 | Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. <i>Leukemia Research</i> , 2010 , 34, 1576-88 | 2.7 | 100 |
| 101 | Management of Transfusional Chronic Iron Overload: Focus on Deferasirox. <i>Clinical Medicine Therapeutics</i> , 2009 , 1, CMT.S1970 | | 1 |
| 100 | Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. <i>Clinical Cancer Research</i> , 2009 , 15, 5002-7 | 12.9 | 87 |
| 99 | Sinusal bradycardia after receiving intermediate or high dose cytarabine: four cases from a single institution. <i>European Journal of Cancer Care</i> , 2009 , 18, 320-1 | 2.4 | 5 |
| 98 | Long term outcome of localized aggressive non-Hodgkin lymphoma treated with a short weekly chemotherapy regimen (doxorubicin, cyclophosphamide, bleomycin, vincristine, and prednisone) and involved field radiotherapy: result of a Gruppo Italiano Multiregionale per lo Studio dei Linfomi e Leucemie (GIMLIFEL) study. <i>Leukemia and Lymphoma</i> , 2009 , 50, 1475-81 | 1.9 | 1 |
| 97 | Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. <i>Haematologica</i> , 2009 , 94, 1250-8 | 6.6 | 56 |

| | | | |
|----|---|------|-----|
| 96 | Hematopoietic stem cell transplantation in thalassemia and related disorders. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2009 , 1, e2009015 | 3.2 | 3 |
| 95 | Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. <i>Haematologica</i> , 2008 , 93, 1385-8 | 6.6 | 101 |
| 94 | Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. <i>Haematologica</i> , 2008 , 93, 741-52 | 6.6 | 145 |
| 93 | Marginal zone B-cell lymphoma arising in donor cells in a Hepatitis-C virus infected patient over 20 years after allogeneic bone marrow transplantation. <i>Leukemia and Lymphoma</i> , 2008 , 49, 2219-21 | 1.9 | |
| 92 | ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin lymphoma: results from an Intergruppo Italiano Linfomi randomized study. <i>Annals of Oncology</i> , 2008 , 19, 763-8 | 10.3 | 6 |
| 91 | Anemia in beta-thalassemia patients targets hepatic hepcidin transcript levels independently of iron metabolism genes controlling hepcidin expression. <i>Haematologica</i> , 2008 , 93, 111-5 | 6.6 | 29 |
| 90 | Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy. <i>Haematologica</i> , 2008 , 93, 951-2 | 6.6 | 73 |
| 89 | Risk of HBV liver disease in isolated antiHbc patients receiving immuno-chemotherapy for non Hodgkin lymphoma. <i>Haematologica</i> , 2008 , 93, e66 | 6.6 | 6 |
| 88 | Risk of malignant lymphoma following viral hepatitis infection. <i>International Journal of Hematology</i> , 2008 , 87, 474-483 | 2.3 | 25 |
| 87 | Interleukin-1B (IL1B) and interleukin-6 (IL6) gene polymorphisms are associated with risk of chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , 2008 , 26, 98-103 | 1.3 | 41 |
| 86 | Unexpected CNS localization in M2 acute myeloid leukemia: a link with past heroin addiction?. <i>American Journal of Hematology</i> , 2008 , 83, 682-3 | 7.1 | 1 |
| 85 | Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients. <i>American Journal of Hematology</i> , 2008 , 83, 717-20 | 7.1 | 18 |
| 84 | Prophylaxis and treatment of hepatitis B in immunocompromised patients. <i>Digestive and Liver Disease</i> , 2007 , 39, 397-408 | 3.3 | 172 |
| 83 | Glucose-6-Phosphate Dehydrogenase Polymorphism and Lymphoma Risk. <i>Tumori</i> , 2007 , 93, 121-123 | 1.7 | 2 |
| 82 | Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2007 , 39, 89-99 | 4.4 | 85 |
| 81 | Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. <i>Bone Marrow Transplantation</i> , 2007 , 39, 189-91 | 4.4 | 12 |
| 80 | Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670). <i>European Journal of Haematology</i> , 2007 , 78, 540-2 | 3.8 | 58 |
| 79 | Sudden cardiac failure in a beta-thalassemia major patient receiving chemotherapy for acute promyelocytic leukemia. <i>Leukemia and Lymphoma</i> , 2007 , 48, 628-9 | 1.9 | 1 |

| | | | |
|----|--|------|-----|
| 78 | Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. <i>Haematologica</i> , 2007 , 92, 612-8 | 6.6 | 111 |
| 77 | Sensorimotor peripheral neuropathy in an elderly AML patient in complete remission while receiving gemtuzumab ozogamicin as maintenance therapy. <i>Annals of Hematology</i> , 2006 , 85, 411-2 | 3 | 3 |
| 76 | The MLL recombinome of acute leukemias. <i>Leukemia</i> , 2006 , 20, 777-84 | 10.7 | 175 |
| 75 | New strategies in the treatment of the thalassemias. <i>Annual Review of Medicine</i> , 2005 , 56, 157-71 | 17.4 | 52 |
| 74 | ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. <i>Journal of Clinical Oncology</i> , 2005 , 23, 9198-207 | 2.2 | 144 |
| 73 | Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials. <i>Annals of Oncology</i> , 2005 , 16, 228-33 | 10.3 | 15 |
| 72 | High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial. <i>Haematologica</i> , 2005 , 90, 793-801 | 6.6 | 29 |
| 71 | VEPEMB in elderly Hodgkin lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. <i>Annals of Oncology</i> , 2004 , 15, 123-8 | 10.3 | 64 |
| 70 | High prevalence of non-HFE gene-associated haemochromatosis in patients from southern Italy. <i>Clinical Chemistry and Laboratory Medicine</i> , 2004 , 42, 17-24 | 5.9 | 6 |
| 69 | New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. <i>Blood</i> , 2004 , 104, 1201-3 | 2.2 | 160 |
| 68 | The role of oxidant injury in the pathophysiology of human thalassemias. <i>Redox Report</i> , 2003 , 8, 241-5 | 5.9 | 39 |
| 67 | The cure of thalassemia by bone marrow transplantation. <i>Blood Reviews</i> , 2002 , 16, 81-5 | 11.1 | 145 |
| 66 | Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and/or interferon at a single center: long-term results. <i>Bone Marrow Transplantation</i> , 2002 , 29, 1-8 | 4.4 | 14 |
| 65 | Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. <i>Blood</i> , 2002 , 100, 17-21 | 2.2 | 235 |
| 64 | Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. <i>Annals of Internal Medicine</i> , 2002 , 136, 667-72 | 8 | 78 |
| 63 | Enhanced macrophagic attack on beta-thalassemia major erythroid precursors. <i>Haematologica</i> , 2002 , 87, 578-83 | 6.6 | 9 |
| 62 | A three or more drug combination as effective therapy for moderate or severe chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2001 , 27, 45-51 | 4.4 | 11 |
| 61 | Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2000 , 25, 401-4 | 4.4 | 153 |

| | | | |
|----|---|------|-----|
| 60 | Trichosporon beigelii: a life-threatening pathogen in immunocompromised hosts. <i>Bone Marrow Transplantation</i> , 2000 , 25, 745-9 | 4.4 | 61 |
| 59 | Bone marrow transplantation from alternative donors for thalassemia: HLA-phenotypically identical relative and HLA-nonidentical sibling or parent transplants. <i>Bone Marrow Transplantation</i> , 2000 , 25, 815-21 | 4.4 | 97 |
| 58 | Regression of multiple hepatic masses in a young patient with thalassaemia. <i>Pediatric Radiology</i> , 2000 , 30, 161-4 | 2.8 | 0 |
| 57 | The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with β thalassemia major. <i>Blood</i> , 2000 , 96, 3624-3629 | 2.2 | 104 |
| 56 | Hepatic iron concentration and total body iron stores in thalassemia major. <i>New England Journal of Medicine</i> , 2000 , 343, 327-31 | 59.2 | 440 |
| 55 | The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with β thalassemia major. <i>Blood</i> , 2000 , 96, 3624-3629 | 2.2 | 9 |
| 54 | The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with beta-thalassemia major. <i>Blood</i> , 2000 , 96, 3624-9 | 2.2 | 53 |
| 53 | Bone Marrow Transplantation in Adult Thalassemic Patients. <i>Blood</i> , 1999 , 93, 1164-1167 | 2.2 | 151 |
| 52 | Images in clinical medicine. Successful treatment of severe thalassemia. <i>New England Journal of Medicine</i> , 1999 , 341, 92 | 59.2 | 1 |
| 51 | Bone marrow transplantation for transfused patients with severe aplastic anemia using cyclophosphamide and total lymphoid irradiation as conditioning therapy: long-term follow-up from a single center. <i>Bone Marrow Transplantation</i> , 1999 , 24, 253-7 | 4.4 | 17 |
| 50 | Second marrow transplants for graft failure in patients with thalassemia. <i>Bone Marrow Transplantation</i> , 1999 , 24, 1299-306 | 4.4 | 25 |
| 49 | Bone Marrow Transplantation in Adult Thalassemic Patients. <i>Blood</i> , 1999 , 93, 1164-1167 | 2.2 | |
| 48 | Bone marrow transplantation in adult thalassemic patients. <i>Blood</i> , 1999 , 93, 1164-7 | 2.2 | 34 |
| 47 | An unusual marrow transplant complication: cardiac myxoma. <i>Bone Marrow Transplantation</i> , 1998 , 21, 825-7 | 4.4 | 10 |
| 46 | Bone marrow transplantation in thalassemia. The experience of Pesaro. <i>Annals of the New York Academy of Sciences</i> , 1998 , 850, 270-5 | 6.5 | 94 |
| 45 | Treatment of iron overload in the "ex-thalassemic". Report from the phlebotomy program. <i>Annals of the New York Academy of Sciences</i> , 1998 , 850, 288-93 | 6.5 | 33 |
| 44 | Evaluation of cardiac status in iron-loaded thalassaemia patients following bone marrow transplantation: improvement in cardiac function during reduction in body iron burden. <i>British Journal of Haematology</i> , 1998 , 103, 916-21 | 4.5 | 47 |
| 43 | Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood. <i>Journal of Clinical Oncology</i> , 1997 , 15, 566-73 | 2.2 | 100 |

| | | | |
|----|--|-----|-----|
| 42 | Limitations of Magnetic Resonance Imaging in Measurement of Hepatic Iron. <i>Blood</i> , 1997 , 90, 4736-4742. | 2.2 | 64 |
| 41 | Phlebotomy to Reduce Iron Overload in Patients Cured of Thalassemia by Bone Marrow Transplantation. <i>Blood</i> , 1997 , 90, 994-998 | 2.2 | 129 |
| 40 | Kaposi's sarcoma after allogeneic bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1997 , 19, 629-31 | 4.4 | 23 |
| 39 | Alpha-interferon treatment of chronic hepatitis C after bone marrow transplantation for homozygous beta-thalassemia. <i>Bone Marrow Transplantation</i> , 1997 , 20, 767-72 | 4.4 | 32 |
| 38 | Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia. <i>Bone Marrow Transplantation</i> , 1997 , 20, 915-20 | 4.4 | 40 |
| 37 | Phlebotomy to Reduce Iron Overload in Patients Cured of Thalassemia by Bone Marrow Transplantation. <i>Blood</i> , 1997 , 90, 994-998 | 2.2 | 1 |
| 36 | Graft-versus-host disease after bone marrow transplantation for thalassemia: an analysis of incidence and risk factors. <i>Transplantation</i> , 1997 , 63, 854-60 | 1.8 | 60 |
| 35 | Limitations of Magnetic Resonance Imaging in Measurement of Hepatic Iron. <i>Blood</i> , 1997 , 90, 4736-4742. | | |
| 34 | Bone marrow transplantation in thalassemia. <i>Cancer Treatment and Research</i> , 1997 , 77, 305-15 | 3.5 | 15 |
| 33 | Marrow transplantation for patients with thalassemia: results in class 3 patients. <i>Blood</i> , 1996 , 87, 2082-2088 | | 178 |
| 32 | Reduced Left Ventricular Contractile Reserve Identified by Low Dose Dobutamine Echocardiography as an Early Marker of Cardiac Involvement in Asymptomatic Patients with Thalassemia Major. <i>Echocardiography</i> , 1996 , 13, 463-472 | 1.5 | 24 |
| 31 | Marrow transplantation for patients with thalassemia: results in class 3 patients. <i>Blood</i> , 1996 , 87, 2082-82. | | 27 |
| 30 | Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies. <i>British Journal of Haematology</i> , 1995 , 89, 757-61 | 4.5 | 106 |
| 29 | Desferrioxamine therapy accelerates clearance of iron deposits after bone marrow transplantation for thalassaemia. <i>British Journal of Haematology</i> , 1995 , 89, 868-73 | 4.5 | 50 |
| 28 | Intravenous chelation therapy during transplantation for thalassemia. <i>Haematologica</i> , 1995 , 80, 300-4 | 6.6 | 23 |
| 27 | Haploidentical bone marrow transplantation from mother to child with advanced leukemia. <i>Bone Marrow Transplantation</i> , 1995 , 16, 529-35 | 4.4 | 19 |
| 26 | Pancreatic beta-Cell Function Before and After Bone Marrow Transplantation for Thalassemia 1995 , 69-72 | | |
| 25 | Bone marrow transplantation in thalassemia: modifications of hepatic iron overload and associated lesions after long-term engrafting. <i>Liver</i> , 1994 , 14, 14-24 | | 35 |

| | | | |
|----|--|------|-----|
| 24 | Hepatitis C virus infection in thalassemia patients undergoing allogeneic bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1994 , 14, 369-72 | 4.4 | 17 |
| 23 | Antibodies to hepatitis C virus in thalassemia. <i>Haematologica</i> , 1994 , 79, 353-5 | 6.6 | 13 |
| 22 | Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide. <i>Bone Marrow Transplantation</i> , 1994 , 13, 197-201 | 4.4 | 5 |
| 21 | Fate of iron stores in thalassaemia after bone-marrow transplantation. <i>Lancet, The</i> , 1993 , 342, 1388-91 | 4.0 | 74 |
| 20 | Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. <i>New England Journal of Medicine</i> , 1993 , 329, 840-4 | 59.2 | 184 |
| 19 | Accelerated programmed cell death (apoptosis) in erythroid precursors of patients with severe beta-thalassemia (Cooley's anemia) [see comments]. <i>Blood</i> , 1993 , 82, 374-377 | 2.2 | 110 |
| 18 | Bone marrow transplantation for thalassemia. <i>Indian Journal of Pediatrics</i> , 1993 , 60, 517-23 | 3 | 3 |
| 17 | Pubertal development in thalassaemic patients after allogeneic bone marrow transplantation. <i>European Journal of Pediatrics</i> , 1993 , 152, 993-7 | 4.1 | 14 |
| 16 | Sudden cardiac tamponade after chemotherapy for marrow transplantation in thalassaemia. <i>Lancet, The</i> , 1992 , 339, 287-9 | 4.0 | 34 |
| 15 | Bone marrow transplantation in adult thalassemia. <i>Blood</i> , 1992 , 80, 1603-1607 | 2.2 | 50 |
| 14 | Bone Marrow Transplantation in Thalassemia. <i>Hematology/Oncology Clinics of North America</i> , 1991 , 5, 549-556 | 3.1 | 33 |
| 13 | New approach to bone marrow transplantation in thalassemia 1991 , 425-428 | | |
| 12 | Bone marrow transplantation in patients with thalassemia. <i>New England Journal of Medicine</i> , 1990 , 322, 417-21 | 59.2 | 501 |
| 11 | A new approach to bone marrow transplantation in thalassemia. <i>Annals of the New York Academy of Sciences</i> , 1990 , 612, 394-7 | 6.5 | 2 |
| 10 | Marrow transplantation for children with acute leukemia: experience of Pesaro. <i>Acta Haematologica</i> , 1989 , 82, 7-11 | 2.7 | 0 |
| 9 | Reversal features of hepatic hemosiderosis and haemochromatosis in thalassemia after bone marrow transplantation. <i>Progress in Clinical and Biological Research</i> , 1989 , 309, 299-314 | | 7 |
| 8 | A comparative trial of posttransplant immunosuppression in patients transplanted for thalassemia. Cyclosporine alone versus cyclosporine, cyclophosphamide, and methotrexate. <i>Transplantation</i> , 1988 , 45, 566-9 | 1.8 | 5 |
| 7 | Bone Marrow Transplantation for Thalassemia: 156 Cases Transplanted in Pesaro. <i>Plant Systematics and Evolution Supplementum = Entwicklungsgeschichte Und Systematik Der Pflanzen Supplementum</i> , 1988 , 187-188 | | |

| | | | |
|---|---|------|-----|
| 6 | Marrow transplantation in patients with advanced thalassemia. <i>New England Journal of Medicine</i> , 1987 , 316, 1050-5 | 59.2 | 103 |
| 5 | Bone marrow transplantation in leukemia: experience of Pesaro. <i>Acta Haematologica</i> , 1987 , 78 Suppl 1, 187-9 | 2.7 | |
| 4 | Marrow transplantation for thalassaemia following busulphan and cyclophosphamide. <i>Lancet, The</i> , 1985 , 1, 1355-7 | 40 | 84 |
| 3 | Current and Future Therapies for β Thalassaemia: A Review Article. <i>European Medical Journal Hematology</i> ,94-104 | | |
| 2 | Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and/or interferon at a single center: long-term results | | 2 |
| 1 | Stem Cell Transplantation774-790 | | |